论文部分内容阅读
目的:探讨奥卡西平口服混悬液单药治疗2岁以下婴幼儿部分性发作癫痫的临床疗效和安全性。方法:收集2岁以下婴幼儿部分性发作癫痫患儿52例,给予奥卡西平口服混悬液单药治疗,起始量为8~10 mg/(kg·d),渐加量至20~40 mg/(kg·d),随访6~18个月,进行自身对照开放性研究,观察其疗效及安全性。结果:应用奥卡西平口服混悬液治疗后,有效率及控制率分别为94.2%、84.6%,8例(15.4%)患儿发生腹泻、呕吐、纳差、皮疹等不良反应。结论:奥卡西平口服混悬液治疗婴幼儿部分性发作癫痫疗效显著,临床应用方便,安全性好,不良反应较少,值得临床推广应用。
Objective: To investigate the clinical efficacy and safety of oral administration of oxcarbazepine monotherapy for partial seizures in infants under 2 years of age. Methods: Fifty-two infants with partial seizures and infants under 2 years of age were enrolled in this study. Patients were given oxcarbazepine oral monotherapy with an initial dose of 8-10 mg / (kg · d) 40 mg / (kg · d), followed up for 6 to 18 months, self-control open study to observe its efficacy and safety. Results: After oral administration of oxcarbazepine, the effective rate and control rate were 94.2%, 84.6%, 8 cases (15.4%) in children with diarrhea, vomiting, anorexia, rash and other adverse reactions. Conclusion: Oralizine oral suspension treatment of infantile partial seizures significant effect of epilepsy, clinical application, safety, adverse reactions less worthy of clinical application.